SON-1010 is under clinical development by Sonnet BioTherapeutics and currently in Phase I for Non-Small Cell Lung Cancer.

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

APX-3330 is under clinical development by Opus Genetics and currently in Phase II for Non-Proliferative Diabetic Retinopathy (NPDR).

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) ...

Shares of Vertex Pharmaceuticals Incorporated VRTX were down 11.4% yesterday after the company announced data from a phase II ...

Vertex stock plummeted Thursday after the company's non ... to peripheral neuropathy pain. Vertex is likely pushing ahead in ...

Diabetic socks are specially designed to keep feet dry, decrease the risk of foot injury, and enhance blood circulation. They are a key part of foot care, which is an important aspect of diabetes ...

“SiteOne Therapeutics is committed to developing non-opioid treatments for conditions that involve hyperexcitability of the peripheral nervous system such as pain and cough. Our strategy is ...

SiteOne Therapeutics is powering up with $100 million to advance its early pipeline of non-opioid therapeutics that target the peripheral ... nonaddictive oral pain treatment slated to arrive ...

Read more on treatments for glaucoma. What it is: The most advanced stage of diabetic eye disease where the retina grows new blood vessels (neovascularization). These fragile blood vessels break and ...

“SiteOne Therapeutics is committed to developing non-opioid treatments for conditions that involve hyperexcitability of the peripheral nervous system such as pain and cough. Our strategy is focused on ...

Neuropathy is nerve damage that often occurs in people with diabetes and as a side effect of chemotherapy. Treatment for neuropathy ... therapy for people with peripheral neuropathy.